Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Acadia nets $271.7mm through FOPO

Executive Summary

Acadia Pharmaceuticals Inc. (psychiatric drug development) netted $271.7mm through the public offering of 7.2mm shares (including the overallotment) at $40. The company will use some of the proceeds to fund the potential commercialization of lead candidate Nuplazid (pimavanserin) for dementia-related psychosis, for which it has a 60% likelihood of approval (8% above average), according to Biomedtracker; an NDA submission is expected next year. The small-molecule serotonin 5-hydroxytryptamine 2A (5-HT2A) receptor antagonist pimavanserin was initially launched in the US in April 2016 for hallucinations and delusions associated with Parkinson’s disease psychosis. In addition to dementia-related psychosis, Nuplazid is also in Phase III for major depressive disorder (a 52% LOA, 1% above average) and in Phase II for schizophrenia (a Phase III trial in July 2019 failed to reach the primary endpoint).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies